L. Haberer

Sequential Group Trial to Determine Gastrointestinal Site of Absorption and Systemic Exposure of Azathioprine

J. Gervasio, Rex O. Brown, T. Abell, 2000, Digestive Diseases and Sciences.

Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months

J. Barrett, P. Adamson, C. Coté, 2009, European Journal of Clinical Pharmacology.

The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men

Christina Wang, R. Swerdloff, A. Matsumoto, 2007 .

Single‐Dose Pharmacokinetics of the CCR9 Receptor Antagonist Vercirnon in Healthy US and Japanese Subjects

K. Hacquoil, T. Hirama, I. McSherry, 2013, Clinical pharmacology in drug development.

Central nervous system uptake kinetics of pentylenetetrazol in the developing rat

L. Haberer, G. Pollack, 1991, Biopharmaceutics & drug disposition.

Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double‐blind, placebo‐, and active‐controlled thorough QT study

M. Russo, L. Haberer, T. Hunt, 2014, Journal of clinical pharmacology.

Chronic stress impairs oxidative metabolism and hepatic excretion of model xenobiotic substrates in the rat.

L. Haberer, J. Browne, J. Márton, 1991, Drug metabolism and disposition: the biological fate of chemicals.

Disposition and protein binding of valproic acid in the developing rat.

L. Haberer, G. Pollack, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates

L. McCarthy, I. McSherry, L. Haberer, 2013, European Journal of Clinical Pharmacology.